Droplet digital PCR-based detection of circulating tumor DNA from pediatric high grade and diffuse midline glioma patients

Elisa Izquierdo, Paula Proszek, Giulia Pericoli, Sara Temelso, Matthew Clarke, Diana M. Carvalho, Alan. Mackay, Lynley V. Marshall, Fernando Carceller, Darren Hargrave, Birgitta Lannering, Zdenek Pavelka, Simon Bailey, Natacha Entz-Werle, Jacques Grill, Gilles Vassal, Daniel Rodriguez, Paul S. Morgan, Tim Jaspan, Angela Mastronuzzi, Mara Vinci, Michael Hubank, and Chris Jones

Division of Molecular Pathology, Institute of Cancer Research, London, UK (E.I., S. T., M.C., D.M.C., A.M., C.J.); Molecular Diagnostics, Royal Marsden Hospital NHS Trust, Sutton, UK (P.P.); Department of Onco-haematology, Cell and Gene Therapy, Bambino Gesù Children’s Hospital-IRCCS, Rome, Italy (G.P., M.V.); Division of Clinical Studies, The Institute of Cancer Research, London, UK (L.V.M., F.C.); Children & Young People’s Unit, Royal Marsden Hospital NHS Trust, Sutton, UK (L.V.M., F.C.); Department of Haematology and Oncology, UCL Great Ormond Street Institute for Child Health, London, UK (D.H.); Department of Pediatrics, Institute of Clinical Sciences, Queen Silvia Children’s Hospital, University of Gothenburg, Gothenburg, Sweden (B.L.); Department of Pediatric Oncology, University Hospital Brno – Children’s Hospital, Brno, Czechia (Z.P.); Department of Paediatric Oncology, Great North Children’s Hospital, Newcastle University Center for Cancer, Newcastle upon Tyne, UK (S.B.); Pediatric Onc-Hematology Department, University Hospital of Strasbourg, Strasbourg, France (N.E.W.); UMR CNRS 7021, Laboratory Bioimaging and Pathologies, Tumoral Signaling and Therapeutic Targets team, Faculty of Pharmacy, Illkirch, France (N.E.W.); Pediatric and Adolescent Oncology and INSERM Unit U981, Team Genomics and Oncogenesis of Pediatric Brain Tumors, Gustave Roussy and Paris Saclay University, Villejuif, France (J.G., G.V.); Medical Physics and Clinical Engineering, Nottingham University Hospital Trust Nottingham University Hospital Trust, Nottingham, UK (D.R., P.S.M.); Department of Radiology, Nottingham University Hospital Trust, Nottingham University Hospital Trust, Nottingham, UK (T.J.)

Corresponding Author: Chris Jones, Division of Molecular Pathology, The Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey, SM2 5NG, UK (chris.jones@icr.ac.uk).

Abstract

Background. The use of liquid biopsy is of potential high importance for children with high grade (HGG) and diffuse midline gliomas (DMG), particularly where surgical procedures are limited, and invasive biopsy sampling not without risk. To date, however, the evidence that detection of cell-free DNA (cfDNA) or circulating tumor DNA (ctDNA) could provide useful information for these patients has been limited, or contradictory.

Methods. We optimized droplet digital PCR (ddPCR) assays for the detection of common somatic mutations observed in pediatric HGG/DMG, and applied them to liquid biopsies from plasma, serum, cerebrospinal fluid (CSF), and cystic fluid collected from 32 patients.

Results. Although detectable in all biomaterial types, ctDNA presented at significantly higher levels in CSF compared to plasma and/or serum. When applied to a cohort of 127 plasma specimens from 41 patients collected from 2011 to 2018 as part of a randomized clinical trial in pediatric non-brainstem HGG/DMG, ctDNA profiling by ddPCR was of limited use due to the small volumes (mean = 0.49 mL) available. In anecdotal cases where sufficient material was available, cfDNA concentration correlated with disease progression in two examples each of poor response in H3F3A_K27M-mutant DMG, and longer survival times in hemispheric BRAF_V600E-mutant cases.

Conclusion. Tumor-specific DNA alterations are more readily detected in CSF than plasma. Although we demonstrate the potential of the approach to assessing tumor burden, our results highlight the necessity for adequate sample collection and approach to improve detection if plasma samples are to be used.
The incorporation of tissue molecular profiling in patients with pediatric high-grade glioma (pHGG), diffuse intrinsic pontine glioma (DIPG) and other diffuse midline glioma (DMG) into clinical practice has been demonstrated to be essential to guide treatment decisions for these patients. However, this requires invasive neurosurgical procedures, which are frequently associated with a risk of morbidity or mortality. These risks are of particular concern for tumors located within the brainstem, such as DIPG, where biopsy is technically very challenging and is associated with a risk of significant complications.

The study of liquid biopsy has emerged as an alternative and/or complementary approach to tumor biopsy. Liquid biopsy analysis is comprised of the study of tumor derived material from any biological fluids including blood, cerebrospinal fluid (CSF), urine, and saliva. In this context, cell-free DNA (cfDNA), extracted from different biofluid sources, is used to assess tumor-specific alterations in a less invasive manner. The fraction of cfDNA derived from tumor cells is known as circulating tumor DNA (ctDNA). A benefit of liquid biopsy analysis is the ability to correlate the presence of driver mutations with tumor burden and response to therapy at multiple time-points, avoiding the risks, costs, and need for the expertise of surgical intervention. In this context, many pediatric gliomas are characterized by hotspot driver mutations (H3.1/H3.3_K27M, H3.3_G34R/V, BRAF_V600E, IDH1_R132H) or by single fusion events (ETV6_NTRK3, KIAA1549:BRAF). This makes them perfect candidates for the use of ctDNA to monitor treatment response enabling early detection of tumor progression over the course of the disease.

The presence of ctDNA from plasma has been demonstrated in a range of pediatric solid tumors. Despite concerns regarding the utility of such approaches in brain tumors, several studies have illustrated that ctDNA can be detected in CSF from a variety of pediatric and adult central nervous system (CNS) malignancies. Similar results have been observed in terms of detectable mutations in ctDNA derived from CSF in patients with pHGG and DIPG by using ampiclon next-generation sequencing approaches (NGS) methodology (SafeSeqS). Similar results have also demonstrated that CSF-derived ctDNA levels increase during disease progression. In adult glioma, use of the MSK-IMPACT capture-based NGS assay identified ctDNA in CSF from around half of patients, with ctDNA levels correlating with disease burden and poor outcome.

Less is known about the utility of plasma-derived DNA from brain tumors toward mutation detection and treatment response monitoring, and in particular in pHGG, DIPG, and other DMG. Pan and colleagues showed the detection of ctDNA by custom capture panel sequencing, derived from 3 mL of plasma in 3/8 pediatric patients with brainstem tumors; of those three, two had undetectable mutations in the plasma ctDNA compared to the ctDNA derived from the CSF. Conversely, a study from Panditharana and colleagues showed detectable levels of ctDNA derived from 1 mL of plasma in 16/20 patients with DMG at diagnosis using ddPCR. Notably, a recent publication described the use of cell-free methylated DNA immunoprecipitation and high-throughput sequencing (cfMeDIP-seq) on ctDNA derived from plasma in a range of adult glioma specimens. Given the importance of methylation-based profiling for subtyping pediatric diffuse glioma, this would be an important technique to assess in the childhood context.
The implementation of ctDNA from plasma and CSF in routine clinical practice represents an important goal for the field. The inclusion criteria for an increasing number of clinical trials require molecular characterization to confirm biomarker positivity. For example, *H3F3A_K27M* and *BRAF_V600E* need to be confirmed in tumors for patients to be eligible for current clinical trials of ONC201 (NCT03418530) or dabrafenib in combination with trametinib (NCT02684058), respectively. This is of particular importance for patients such as those with DIPG, where tissue biopsy remains an invasive procedure, not without complications. In addition, the analysis of ctDNA can provide a unique opportunity to assess therapeutic response to a targeted agent, as well as to track tumor evolution in response to therapy, and to identify potential resistance mechanisms that may inform novel treatment options at relapse.

To this end, we sought to explore whether molecular alterations could be identified in liquid biopsy samples from pHGG, DIPG, and other DMG patients. ddPCR assays were validated and applied to quantify ctDNA levels derived from plasma, serum, and CSF. We also explored whether circulating DNA concentrations correlated with tumor burden and multimodal radiological indicators of response and tumor progression using samples collected within a clinical trial in nonbrainstem pHGG/DMG.

### Methods

#### Cases

All patient samples were collected after signed consent to either the HERBY or BIOMEDE translational research programs, or local Institutional Research Board, under full Research Ethics Committee approval at each participating center. A total of 44 samples from different sources of liquid biopsy sample sources (plasma *n* = 27, serum *n* = 6, CSF *n* = 10, and Cyst fluid *n* = 1), were collected from local studies (Royal Marsden Hospital *n* = 26) and collaborators (Ospedale Pediatrico Bambino Gesù *n* = 8 and BIOMEDE *n* = 10). Samples corresponding to 33 patients harbored mutations identified in the tissue tumor sample by next-generation sequencing (whole-exome sequencing and capture panel sequencing assays). In addition, 127 plasma aliquots from different time-points, were available from 41 HERBY patients, harboring driving mutations identified by whole-exome-sequencing of pre-treatment tissue tumor samples.

#### Liquid Biopsy Samples

Where possible, up to 10 mL of peripheral blood was collected into Cell-Free DNA Collection Tubes (Streck, La Vista). Samples were centrifuged twice for 10 min, first at 1600 g and at up to 16,000 g to remove cellular contents and/or debris. Samples were stored at −80°C until cfdNA extraction. Local protocols to isolate plasma and CSF were used for the remaining liquid biopsies cases, collected from different sources. cfdNA isolation from plasma and CSF supernatant was performed using the QIAamp circulating nucleic acid kit (Qiagen, 55114) following quantification using the Qubit fluorometer (ThermoFisher Scientific, dsDNA HS Assay kit, Q32854) and fragment analysis by 2200 and 4200 TapeStation (Agilent, Genomic DNA ScreenTape 5067–5366).

### Droplet Digital PCR

Custom TaqMan-based quantitative PCR genotyping assays (Applied Biosystems, Thermo Scientific and IDT, Integrated DNA Technologies) were designed to specifically detect genetic abnormalities (mutations) (Supplementary Table S2). Commercially available assays were used to identify MYCN amplification (MYCN Hs00201049_cn, control region 4403316 or 4403326, Applied Biosystems, Thermo Scientific) and *H3F3A_K27M* (*H3F3A_K27M* dHsaCP2500510; *H3F3A_WT* dHsaCP2500511, Bio-Rad) as well as *H3F3A_G34R* (*H3F3A_G34R* dHsals2502038; *H3F3A_WT* dHsals2502309, Bio-Rad). The assay limit of detection (LoD) was assessed by performing serial dilutions of the mutant DNA in a constant concentration of wild-type DNA (1:10, 1:100, 1:1000 and 1:10,000) and run in duplicate using 5 ng of DNA. The LoD was calculated as the fractional abundance of the neat mutant sample divided by the lowest dilution with detectable mutant copies (at least two mutant droplets). For each assay, three controls were run in duplicates including: one non-template control, one wild-type control (fragmented Promega DNA at 1 ng/µL), and one positive control harboring the alteration of interest.

The Bio-Rad QX200 ddPCR system was used, which allows the detection of rare DNA target copies with high sensitivity. DNA was randomly encapsulated into approximately 15,000 oil nanoliter-sized droplets, using the Automated Droplet Generator (BioRad, QX200 AutoDG), containing ddPCR Supermix for probes (no dUTP) (BioRad, 1863024), genotyping assay (specific per alteration), water, and the DNA of interest. The PCR reaction was performed in a thermocycler plates were then placed on the droplet reader where the droplets are streamed individually through a detector and signals from mutant positive (FAM), wild-type (VIC/HEX), double-positive (FAM and VIC/HEX), and negative droplets (empty) are counted to provide absolute quantification of DNA in digital form. The mutant allele concentration (CMUT) and wild-type allele concentration (CWt) were calculated with Quantasoft Analysis Pro (BioRad), the mutant allele fraction (AFddPCR) and the concentration of cfdNA in the CSF or plasma (CcfdNA ng/mL) were calculated with the following calculations as previously described in:

\[
AF_{ddPCR} = \frac{CMUT}{CMUT + CWt}
\]

\[
CMUT\_ori = V_{PCR} \times CMUT \times V_{ELU}/V_{DNA-PCR} \times V_{SAMPLE}
\]

\[
CWt\_ori = V_{PCR} \times CWt \times V_{ELU}/V_{DNA-PCR} \times V_{SAMPLE}
\]
Izquierdo et al. Liquid biopsy of pediatric HGG and DIPG

Results

ddPCR Assay Validation for the Detection of ctDNA from Liquid Biopsies

Liquid biopsies from multiple biological sources (plasma, serum, cerebrospinal fluid (CSF), and cystic fluid) were collected from 32 pHGG and DIPG patients with known molecular alterations from the sequencing of their tumor tissue. These patients harboured somatic mutations in H3F3A (K27M and G34R), BRAF (V600E), ACVR1 (G328V), IDH1 (R132H and R132S), TP53 (R282W), and PIK3CA (E542K and H1047R), and one had MYCN amplification. The first goal was to develop a robust detection method for these genetic alterations. To do this, customized and commercially available assays for ddPCR were validated for the identification of patient-specific molecular alterations. Each genotyping assay was tested by using a positive sample harboring the specific alteration of interest, and the variant allele frequency (VAF) was compared between ddPCR and NGS, with an observed correlation of $r^2 = 0.9543$ (Figure 1A).

To assess the limit of detection (LoD) of point mutation detection assays, mutant DNA samples were serially diluted 10-fold in wild-type genomic DNA (1/10, 1/100, 1/1000, and 1/10,000). Genomic DNA from tissue was fragmented and a total DNA input of 5 ng was utilized to simulate the anticipated low amount of ctDNA. LoD was calculated as the VAF of the neat sample divided by the lowest dilution with detectable signal for mutant, with at least two droplets containing mutant DNA. Two different H3F3A_K27M assays were assessed, one commercially available from Bio-Rad and one reported by Stallard and colleagues. Both assays performed well, obtaining a good droplet separation between FAM and VIC/HEX labels, with a similar LoD (Bio-Rad = 0.793% and custom = 0.791%) (Figure 1B-E). In addition, no mutant droplets were observed in any of the wild-type template control DNA included per assay in each run. By using 5 ng of DNA, LoD ranged from 0.041% (PIK3CA_E542K) to 0.993% (TP53_C238Y), with a median of 0.203% (Supplementary Table S1) and (Supplementary Figure S1).

The MYCN amplification assay contained two probes, one within the MYCN gene and one in a control region at chromosome 5p15.33. The amplification assay was tested by comparing the ratio of copies/µL of MYCN to the control gene (Supplementary Figure S2A). Two ctDNA-plasma positive samples from MYCN-neuroblastoma patients were used for the assay validation, with tissue samples for each patient used as a positive control and run in duplicate. MYCN amplification was detected in the DNA derived from the tissue (Supplementary Figure S2B,D) and the ctDNA isolated from plasma (Supplementary Figure S2C,E). The ctDNA samples taken at diagnosis from the two patients showed a fold-amplification of 32 and 110.

Statistical Analysis

Statistical analysis was carried out using GraphPad Prism 8, using one-way ANOVA with multiple testing correction. An adjusted $P$-value of less than .05 was considered significant.
A cohort of 43 liquid biopsy samples from the 32 patients, which included plasma (n = 27), serum (n = 6), CSF (n = 9) and cyst fluid (n = 1) (Figure 2A). The average volume of fluid obtained was 3.14 mL (SD = 1.2) for plasma, 2 mL (SD = 0.4) for serum, and 1.74 mL (SD = 1.5) for CSF (Figure 2B). From patient 131-T, a large volume (350 mL) of cystic fluid was collected at time of resection and 35 mL were used for cfDNA extraction. The mean cfDNA concentration was 5.2 ng/mL (SD = 4.4) from plasma samples, 110.8 ng/mL (SD = 179.9) from serum and 80.33 ng/mL (SD = 184.2) from CSF (Figure 2C). 1012 ng/mL were obtained from the cyst fluid sample.

Molecular alterations were found in a total of 16 ctDNA samples, including those derived from plasma (7/27, 26%), CSF (6/9, 67%), serum (2/6, 33%) and the only cystic fluid specimen available. Variants included H3F3A_K27M (n = 7), IDH1_R132H (n = 1), PIK3CA_H1047R (n = 1), PIK3CA_E542K (n = 1), ACVR1-G328V (n = 1), TP53_C238Y (n = 1), and TP53_R282W (n = 2) (Table 1). Although not formally significant due to small numbers and high degree of variability, the average of positive droplets was higher in ctDNA derived from CSF (median = 735.7, SD = 1582), than from plasma (median = 4.7, SD = 3.9) and serum (median = 4.5, SD = 3.53) (P = .5879 and P = .8167, respectively, one-way ANOVA, Tukey’s multiple comparisons test) (Figure 2D). Similarly, the average VAF was higher in ctDNA derived from CSF (median = 15.33%, SD = 21.54%) than from plasma (median = 0.78%, SD = 0.31%) and serum (median = 0.22%, SD = 0.16%) (P = .2867 and P = .5633, respectively, one-way ANOVA, Tukey’s multiple comparisons test) (Figure 2E). The highest number of positive droplets (10,944, VAF = 42.68%) was found in the cystic fluid. More than two-thirds (70%) of samples from all biosources in which there were no detectable alterations were from DIPG or DMG patients. Paired CSF/cyst fluid and plasma/serum were available for five patients—of these, two alterations were detected in both liquid biopsy sources and for the remaining three cases variants were only identified in the CSF (all of whom were also DIPG or DMG). For patient 045-T, who presented with a hemispheric HGG with hypermutator phenotype (210 mutations per Mb), TP53_R282W was identified in ctDNA derived from CSF (VAF = 49.34%) and the plasma (VAF = 0.12%). In addition, patient-131-T, with a right thalamic glioma, H3F3A_K27M was identified in the cystic fluid (VAF = 42.68%) and the plasma (VAF = 0.85%). Although the formal threshold for a positive sample was set as at least two positive droplets, a single positive droplet was found in seven cases, including five ctDNA derived from plasma (H3F3A_K27M n = 4, and ACVR1-G328V n = 1) and two CSF (H3F3A_K27M n = 2).

By assessing the DNA integrity with a TapeStation electrophotometric analyzer, ctDNA was found in 8/13 samples with detectable cfDNA (Figure 2F). Of note, 4/6 cfDNA extracted from serum presented a smear of fragmented DNA including genomic DNA (Figure 2G), whilst one CSF sample (1-16-3200, H3F3A_K27M positive), had a pronounced gDNA contamination and had the lowest VAF of ctDNA samples (0.05%) (Figure 2H).

Finally, a custom pediatric brain tumor fusion panel29,33 was used to detect a known ETV6-NTRK3 fusion in the CSF from a single infant glioma patient (OPBG_INF_035). 30 ng of cfDNA extracted from 4.5 mL of CSF was run on the capture panel, with 23 reads supporting the fusion detected (Supplementary Figure S3).
Exploring the Use of Liquid Biopsy in the HERBY Clinical Trial Cohort

To assess the utility of liquid biopsies for molecular diagnostics and to monitor disease progression, we studied genetic alterations in cfDNA derived from plasma from longitudinal samples from the well-annotated HERBY trial in non-brainstem pHGG (NCT01390948). Blood samples were taken at up to five different time-points during the course of treatment, with plasma isolated locally and sent to our laboratory. cfDNA was extracted from 127 plasma samples from 41 patients, selected for tumors harboring alterations in H3F3A, IDH1, BRAF, or MYCN (Figure 3A).

The mean volume of plasma from which cfDNA was extracted was 0.49 mL (SD = 0.35, excluding one sample from which 4 mL of plasma were used for extraction) (Figure 3B).

The mean yield of total DNA extracted from plasma was 2.52 ng (SD = 2.83, excluding the four cases with high levels of genomic DNA) (Figure 3C). The mean of total DNA yield extracted per mL of plasma was 5.25 ng (SD = 5.21, excluding the four cases with high levels of genomic DNA) (Figure 3D). The DNA samples were run undiluted and the mean of DNA ddPCR input was 1.76 ng (SD = 2.04). Disappointingly, none of the HERBY cfDNA samples tested for the known genetic alterations were...
positive (>two mutant droplets for point mutations and >4-fold for MYCN amplification). However, there were four cases where one positive droplet was found (BRAF_V600E, n = 2; H3F3A_K27M, H3F3A_G34R, n = 1 each). All four patients received bevacizumab and had stable disease as their best radiological response. ctDNA concentration was compared between molecular subgroups. Although there was no significant difference between subgroups at baseline (P = .1026, one-way ANOVA), there was a trend of higher concentration of ctDNA in BRAF_V600E positive patients compared to H3F3A_K27M and H3F3A_G34R (P = .0547 and P = .0661, respectively, one-way ANOVA, Dunnett’s multiple comparisons test) (Figure 3E). DNA integrity was measured by using TapeStation, showing four different types of DNA size distribution: 33 samples presented a detectable ctDNA peak (~170 bp) (Figure 3F), five samples contained a high amount of genomic DNA contamination (>55 kb) (Figure 3G), 12 samples showed detectable ctDNA and genomic DNA peaks (Figure 3H), whilst in the remaining 75 samples no DNA was detectable (Figure 3I).

Finally, although we were not able to reliably detect ctDNA in the HERBY plasma samples, we explored the correlation of ctDNA concentrations to disease burden and tumor progression. When assessing the changes in ctDNA concentrations over the course of the individual patient’s disease (Supplementary Figure S4), anecdotal variations across longitudinal time-points were observed in four patients. Two DMGs, both H3F3A_K27M mutated, exhibited increased ctDNA concentrations at later timepoints, corresponding with a relatively short time to progression in these cases. The first (HERBY032) was a 12.8-year-old boy who underwent a near-total resection prior to treatment with bevacizumab and chemoradiotherapy. He displayed local recurrence at 5.5 months, though there was a marked increase in ctDNA concentration 3 months earlier. He died at 16.4 months postrandomization (Figure 4A). The second (HERBY096) was a 12.6-year-old boy, also on the bevacizumab arm, but who was eligible for biopsy only, and had local progression at 4.0 months. There was a substantial ctDNA increase in the subsequent plasma sample two months later, and he died of disease at 8.7 months (Figure 4B).

Conversely, two hemispheric glioblastomas with BRAF_V600E mutations showed a reduction in ctDNA concentration from baseline and early time-points, corresponding to longer progression-free survival. HERBY063 was a 10.5-year-old boy who underwent three resections and survived for 28.5 months postrandomization to bevacizumab plus chemoradiotherapy. There was a marked decrease in ctDNA concentration at the earliest timepoints in the first two months, and prior to later local recurrence with slow growth at 8 months (Figure 5A). Finally, HERBY078 was a 13.8-year-old girl treated with temozolomide and radiotherapy alone, and also displayed a substantial initial decrease in ctDNA. She progressed at 10 months locally and below the skull base, with evidence of parotid gland metastatic spread. Nonetheless, she survived on treatment for 27.4 months before succumbing to her disease (Figure 5B).

Table 1. Summary of Liquid Biopsy Samples With Detectable ctDNA From pHGG/DIPG Patients

| Patient ID | ddPCR Assay ID | SAMPLE type | Volume for cDNA (ng/mL) | VAF Mutant Droplets | Wild-type Droplets | cDNA Mutant ng/mL | cDNA Wild-Type ng/mL |
|------------|----------------|-------------|-------------------------|---------------------|-------------------|-----------------|---------------------|
| 013-T      | H3F3A-K27M     | Plasma      | 2.7                     | 2.451               | 10                | 398             | 0.028               | 1.131               |
| 045-T      | TP53-R282W     | CSF         | 5                       | 49.343              | 3945              | 4050            | 271.913             | 279.585             |
| 045-T      | TP53-R282W     | Plasma      | 5                       | 0.118               | 3                 | 2540            | 0.021               | 18.313              |
| 054-T      | H3F3A-G34R     | Plasma      | 5                       | 0.468               | 2                 | 425             | 0.007               | 1.561               |
| 106-T      | IDH1-R132H     | Plasma      | 3.5                     | 0.335               | 11                | 3272            | 0.029               | 8.844               |
| 120-T      | H3F3A-G34R     | Plasma      | 3                       | 1.143               | 2                 | 173             | 0.005               | 0.422               |
| 131-T      | H3F3A-K27M     | Cyst        | 38.5                    | 42.68               | 10944             | 14698           | 367594              | 541.671             |
| 131-T      | H3F3A-K27M     | Plasma      | 2                       | 0.85                | 3                 | 350             | 0.009               | 1.048               |
| 15-3381    | H3F3A-K27M     | CSF         | 1                       | 3.646               | 7                 | 185             | 0.044               | 1.177               |
| 16120B     | PIK3CA-E542K   | Serum       | 2                       | 0.072               | 7                 | 9674            | 0.291               | 472.795             |
| ICR-B134   | H3F3A-K27M     | Serum       | 1.3                     | 0.39                | 2                 | 511             | 0.015               | 3.934               |
| ICR-B276   | PIK3CA-H1047R  | Plasma      | 1.2                     | 0.166               | 2                 | 1727            | 0.006               | 5.098               |
| ICR-CXJ-026| TP53-C283Y     | CSF         | 2.5                     | 2.073               | 4                 | 189             | 0.013               | 0.633               |
| ICR-CXJ-028| ACVR1-G328V    | CSF         | 1.8                     | 35.737              | 446               | 802             | 1.472               | 2.662               |
| I-16-3200  | H3F3A-K27M     | CSF         | 0.7                     | 0.051               | 3                 | 5916            | 0.071               | 159.274             |
| I-16-855   | H3F3A-K27M     | CSF         | 1.5                     | 1.149               | 9                 | 774             | 0.054               | 4.703               |

Shown are the mutations assessed by ddPCR, the biological source material, volume used for the ddPCR assay, variant allele frequency (VAF), number of mutant and wild-type droplets as well as concentration of mutant and wild-type ctDNA.
**Discussion**

This study describes the validation of a number of ddPCR assays for the detection of point mutations in cfDNA. These include key genes commonly altered in pHGG, DIPG, and other DMG, including *H3F3A, IDH1, PIK3CA, BRAF, ACVR1*, and *TP53*, as well as amplification of *MYCN*. By applying this methodology to cfDNA, tumor mutations were detectable in CSF, cystic fluid, plasma, and serum derived from pHGG and DIPG patients. In accordance with other studies, it was found that cfDNA was present at a higher percentage and with greater VAFs in cfDNA derived from CSF compared to plasma and/or serum specimens (~67% compared to 26% and 33% samples, respectively); these data support the use of CSF over plasma as source of tumor DNA for molecular profiling. The detection range of cfDNA in CSF has been fairly consistent among studies, ranging from 66 to 84%. 20, 23–25, 39 whilst there is little concordance for plasma samples (16–80%). 20, 23–25, 39 Another possible reason for lower levels of ctDNA isolated from plasma and/or serum is the presence of background genomic DNA from non-malignant cells. In particular, it was observed that radiotherapy might disrupt the BBB allowing ctDNA to be released into the bloodstream. 22, 23 Another possible reason for lower levels of ctDNA isolated from plasma and/or serum is the presence of background genomic DNA from non-malignant cells. In particular, it was observed that radiotherapy might disrupt the BBB allowing ctDNA to be released into the bloodstream. 22, 23 Another possible reason for lower levels of ctDNA isolated from plasma and/or serum is the presence of background genomic DNA from non-malignant cells. In particular, it was observed that radiotherapy might disrupt the BBB allowing ctDNA to be released into the bloodstream. 22, 23
that no ctDNA was detected in samples presenting highly fragmented cellular DNA, presumably derived from cells undergoing necrosis. Samples presenting higher levels of genomic DNA in our cohorts were mostly derived from external institutions where blood samples were not taken using collection tubes containing a preservative stabilizer of nucleated blood cells such as Streck or PAXgene blood cfDNA tubes. The use of these tubes is highly recommended to prevent cell lysis, and when this is not possible samples taken in EDTA tubes should be processed within 2 h of blood withdrawn.

Longitudinal plasma samples from HERBY, the largest randomized clinical trial in non-brainstem pHGG, represented a unique cohort to test the utility of such approaches for disease monitoring. Unfortunately, at the time of study initiation in 2011, the protocol allowed for only small fluid volumes to be taken, as liquid biopsy approaches had not yet been considered, and it is unfortunate that no ctDNA could be detected from such limited amounts. This is an important consideration for future trials, with at least 4 mL of plasma required for liquid biopsy tests used in clinical practice such as Guardant360. Despite this, cfDNA concentrations themselves, when detectable above baseline, correlated with early disease progression and poor outcome in two patients with K27M mutated DMG, and a better outcome for two patients with BRAF_V600E mutated hemispheric GBM patients.

As cellular DNA contamination can affect the sensitivity of ctDNA detection, some studies have applied in-silico and in vitro size selection to achieve higher sensitivity evaluation of ctDNA. However, this needs to be further verified as size selection after cfDNA extraction might contribute to potential loss of ctDNA material. Another strategy that Panditharatna and colleagues used in their study, which detected ctDNA in 80% of diffuse midline gliomas at diagnosis/upfront therapy, was a pre-amplification step of 9 cycles. This could explain their high detection rate and should be further validated to assess the potential false positive rate introduced by pre-amplification. Newer strategies combining the use of unique molecular identifiers (UMIs), to facilitate the identification of single DNA molecules from PCR duplicates, with deep sequencing, are promising strategies to detect ctDNA. In addition, this strategy sequences a list of genes that can be customized allowing the detection of multiple genes, which can be valuable to track emergence of resistance alterations. In this context, Cell3 Target (Nonacus, oncology) offers calling of mutations down to 0.1% of VAF from as little as 10 ng ctDNA.

Figure 4. Correlation of plasma cfDNA concentration and poor response in DMG-K27M. (A) HERBY032, diffuse midline glioma, WHO grade IV H3F3A_K27M mutant, event-free survival (EFS) of 5.5 months, overall survival (OS) of 16.4 months. cfDNA concentrations (y axis) plotted against time from randomization (days). Resections are marked with an X. Below, axial T2-weighted Fluid and Attenuation Inversion Recovery (FLAIR) MRI scans at different time-points of the patient’s disease, with white arrows highlighting an enlarging hyperintense abnormality at the cavity margins. The shaded box represents the initial 6-week treatment of RT/TMZ with bevacizumab. Subsequent to this, there were repeated cycles of TMZ every 28 days, and bevacizumab every 2 weeks, until the end-point. (B) HERBY096, diffuse midline glioma, WHO grade IV, H3F3A_K27M mutant, EFS of 4 months, OS of 8.7 months. cfDNA concentrations (y axis) plotted against time from randomization (days). Resections are marked with an X. Below, axial T2-weighted or T1 post-gadolinium MRI scans at different time-points of the patient’s disease, with white arrows highlighting a new focus of enhancement. The shaded box represents the initial 6-week treatment of RT/TMZ with bevacizumab. Subsequent to this, there were repeated cycles of TMZ every 28 days, and bevacizumab every 2 weeks, until the end-point.
Figure 5. Correlation of plasma cfDNA concentration and better outcome in hemispheric BRAF_V600E mutant GBM. (A) HERBY063, hemispheric glioblastoma, WHO grade IV, BRAF_V600E mutant, event-free survival (EFS) of 8 months, overall survival (OS) of 28.5 months. cfDNA concentrations (y axis) plotted against time from randomization (days). Resections are marked with an X. Below, axial T2-weighted or T1 post-gadolinium MRI scans at different time-points of the patient disease, with white arrow highlighting an increased T2 abnormality, and the black arrow showing the progressive enhancing tumor. The shaded box represents the initial 6-week treatment of RT/TMZ with bevacizumab. Subsequent to this, there were repeated cycles of TMZ every 28 days, and bevacizumab every 2 weeks, until the end-point. (B) HERBY078, hemispheric glioblastoma, WHO grade IV, BRAF_V600E mutant, EFS of 10 months, OS of 27.4 months. cfDNA concentrations (y axis) plotted against time from randomization (days). Resections are marked with an X. Below, axial T2-weighted MRI scans at different time-points of the patient disease, with white arrows highlighting a new parotid lesion, and the black arrow indicating the primary site recurrence. The shaded box represents the initial 6-week treatment of RT/TMZ. Subsequent to this, there were repeated cycles of TMZ every 28 days until the end-point.
input by incorporating UMIss into targeted NGS customised gene panel.

In summary, we could identify tumor-specific DNA alterations more readily in CSF than plasma, demonstrating the feasibility of tracking tumor response, but also highlighting the importance of sufficient plasma volumes and additional techniques that could enhance yield in these samples. This is particularly critical to avoid the risks associated with repeated sampling of CSF for serial monitoring over time in children with this disease.

Supplementary Data

Supplementary data are available at Neuro-Oncology Advances online.

Keywords

cfDNA | ctDNA | plasma | CSF | DIPG | HGG

Funding

This work was supported by Christopher’s Smile, the CRIS Cancer Foundation, Abbie’s Army, and Cancer Research UK. M.V. is a Children with Cancer UK Fellow. The HERBY clinical trial was carried out as a collaboration between the European Innovative Therapies for Children with Cancer (ITCC) consortium, the SIOPE Brain Tumour Group, the Australian Children’s Cancer Trials Group (ACCT), and the C-17 Council (Canada).

Acknowledgments

We would like to thank the local investigators, pathologists, and radiologists who took part in the HERBY study, and the patients and families who consented to inclusion in the translational research program. The BIOMEDE trial was carried out as a collaboration between the European Innovative Therapies for Children with Cancer (ITCC) consortium, the SIOPE Brain Tumour Group, and the Australian Children’s Cancer Trials Group (ACCT). We acknowledge NHS funding to the NIHR Biomedical Research Centre at The Royal Marsden and the ICR, and Experimental Cancer Medicine Centre (ECMC) and Royal Marsden Cancer Charity (RMCC) funding to the Paediatric Oncology Drug Development Team at The Royal Marsden and the ICR. F.C. is partly funded by The Giant Pledge via the Royal Marsden Cancer Charity. D.H. is supported by funding from the NIHR Great Ormond Street Hospital Biomedical Research Centre. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health.

Conflict of interest statement The translational research study of the HERBY (study number BO25041; clinicaltrials.

Authorship Statement E.I., M.H., and C.J. conceived the study. E.I. and P.P. carried the limit of detection assays and analyzed data. E.I., S.T., and M.C. carried out molecular profiling. E.I., D.C., and A.M. carried out molecular analysis. L.V.M., F.C., D.H., B.L., Z.P., S.B., N.E.-W., J.G., G.V., and M.V. provided samples and clinical annotation. D.R., P.S.M., and T.J. carried out a radiological evaluation from the HERBY clinical trial. E.I. and C.J. wrote the manuscript.

References

1. Ramkissoon SH, Bandopadhayay P, Hwang J, et al. Clinical targeted exome-based sequencing in combination with genome-wide copy number profiling: precision medicine analysis of 203 pediatric brain tumors. Neuro Oncol. 2017;19(7):986–996.
2. Koschmann C, Wu Y-M, Kumar-Sinha C, et al. Clinically integrated sequencing alters therapy in children and young adults with high-risk glial brain tumors. JCO Precision Oncol. 2018;2(1):1–34.
3. Hamisch C, Kickingereger P, Fischer M, Simon T, Ruge MI. Update on the diagnostic value and safety of stereotactic biopsy for pediatric brainstem tumors: a systematic review and meta-analysis of 735 cases. J Neurosurg Pediatr. 2017;20(3):261–268.
4. Gupta N, Goumnerova LC, Manley P, et al. Prospective feasibility and safety assessment of surgical biopsy for patients with newly diagnosed diffuse intrinsic pontine glioma. Neuro Oncol. 2018;20(11):1547–1555.
5. Akshulakov SK, Kerimbayev TT, Biryuchkov MY, Urunbayev YA, Farhadi DS, Byvaltsev YA. Current trends for improving safety of stereotactic brain biopsies: advanced optical methods for vessel avoidance and tumor detection. Front Oncol. 2019;9:947.
6. Mackay A, Burford A, Carvalho D, et al. Integrated Molecular Meta-Analysis of 1,000 Pediatric High-Grade and Diffuse Intrinsic Pontine Glioma. Cancer Cell. 2017;32(4):520–537.e5.
7. Hawksins C, Walker E, Mohamed N, et al. BRAF-KIAA1549 fusion predicts better clinical outcome in pediatric low-grade astrocytoma. Clin Cancer Res. 2017:20(17):4790–4798.
8. Knezevich SR, McFadden DE, Tao W, Lin JF, Sorensen PH. A novel ETV6-NTRK3 gene fusion in congenital fibrosarcoma. Nat Genet. 1998;18(2):184–187.
9. Chedicard M, Boyault S, Colmet Daage L, et al. Genomic copy number profiling using circulating free tumor DNA highlights heterogeneity in neuroblastoma. Clin Cancer Res. 2016;22(22):5564–5573.
10. Combaret V, Iacono I, Bellini A, et al. Detection of tumor ALK status in neuroblastoma patients using peripheral blood. Cancer Med. 2015;4(4):540–550.
11. Hayashi M, Chu D, Meyer CF, et al. Highly personalized detection of minimal Ewing sarcoma disease burden from plasma tumor DNA. Cancer. 2016;122(19):3015–3023.
12. Klega K, Imamovic-Tuco A, Ha G, et al. Detection of Somatic Structural Variants Enables Quantification and Characterization of Circulating Tumor DNA in Children With Solid Tumors. JCO Precis Oncol. 2018;2018(2):1–13. 2018:10.1200/PO.1217.00285
13. Jiménez I, Chicard M, Colmet-Daage L, et al. Circulating tumor DNA analysis enables molecular characterization of pediatric renal tumors at diagnosis. Int J Cancer. 2019;144(1):68–79.
14. Krumbholz M, Hellberg J, Steif B, et al. Genomic EWSR1 Fusion Sequence as Highly Sensitive and Dynamic Plasma Tumor Marker in Ewing Sarcoma. Clin Cancer Res. 2016;22(17):4366–4365.
15. Bettgeowda C, Sausen M, Leary RJ, et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci. Transl. Med. 2014;6(224):224ra224.
16. Wang Y, Springer S, Zhang M, et al. Detection of tumor-derived DNA in cerebrospinal fluid of patients with primary tumors of the brain and spinal cord. Proc Natl Acad Sci U S A. 2015;112(31):9704–9709.
17. Pan W, Gu W, Nagpal S, Gephart MH, Quaker SR. Brain tumor mutations detected in cerebral spinal fluid. Clin Chem. 2015;61(3):514–522.
18. Li Y, Pan W, Connolly ID, et al. Tumor DNA in cerebral spinal fluid reflects clinical course in a patient with melanoma leptomeningeal brain metastases. J Neurooncol. 2016;128(1):93–100.
19. Pentsova EI, Shah RH, Tang J, et al. Evaluating Cancer of the Central Nervous System Through Next-Generation Sequencing of Cerebrospinal Fluid. J Clin Oncol. 2016;34(20):2404–2415.
20. De Mattos-Arruda L, Mayor R, Ng CKY, et al. Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma. Nat Commun. 2015;6:8839.
21. Huang TY, Piunti A, Lulla RR, et al. Detection of Histone H3 mutations in cerebrospinal fluid-derived tumor DNA from children with diffuse midline glioma. Acta Neuropathol Commun. 2017;5(1):28.
22. Stallard S, Saveleff MG, Wierzbicki K, et al. CSF H3F3A K27M mutating tumor DNA copy number quantifies tumor growth and in vitro treatment response. Acta Neuropathol Commun. 2018;6(1):80.
23. Panditharutna E, Kilburn LB, Aboina MS, et al. Clinically relevant and minimally invasive tumor surveillance of pediatric diffuse midline gliomas using patient-derived liquid biopsy. Clin Cancer Res. 2018;24(23):5850–5859.
24. Pan C, Diplas BH, Chen X, et al. Molecular profiling of tumors of the brainstem by sequencing of CSF-derived circulating tumor DNA. Acta Neuropathol. 2019;137(2):297–306.
25. Miller AM, Shah RH, Pentsova EI, et al. Tracking tumour evolution in glioma through liquid biopsies of cerebrospinal fluid. Nature. 2019;565(7741):654–658.
26. Nassiri F, Chakravarthy A, Feng S, et al. Detection and discrimination of intracranial tumors using plasma cell-free DNA methylomes. Nat Med. 2020;26(7):1044–1047.
27. Izquierdo E, Yuan L, George S, et al. Development of a targeted sequencing approach to identify prognostic, predictive and diagnostic markers in paediatric solid tumours. Oncotarget. 2017;8(67):112036–112050.
28. George SL, Izquierdo E, Campbell J, et al. A tailored molecular profiling programme for children with cancer to identify clinically actionable genetic alterations. European J Cancer (Oxford, England: 1990). 2019;121:224–235.
29. Mackay A, Burford A, Molinari V, et al. Molecular, pathological, radiological, and immune profiling of non-brainstem pediatric high-grade glioma from the HERBY phase II randomized trial. Cancer Cell. 2018;33(5):829–842.e825.
30. Garcia-Murillas I, Schiavon G, Weigelt B, et al. Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer. Sci Transl Med. 2015;7(302):302ra133.
31. O’Leary B, Hrebiern S, Beaney M, et al. Comparison of BEAMing and Droplet Digital PCR for Circulating Tumor DNA Analysis. Clin Chem. 2019;65(11):1405–1413.
32. Wen PY, Macdonald DR, Reardon DA, et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol. 2010;28(11):1963–1972.
33. Clarke M, Mackay A, Ismer B, et al. Infant high grade gliomas comprise multiple subgroups characterized by novel targetable gene fusions and favorable outcomes. Cancer Discov. 2020;10(7):942–963.
34. Grill J, Massimino M, Boufret E, et al. Phase II, open-label, randomized, multicenter trial (HERBY) of Bevacizumab in pediatric patients with newly diagnosed high-grade glioma. J Clin Oncol. 2018;36(10):951–958.
35. Rodriguez D, Chambers T, Warmuth-Metz M, et al. Evaluation of the implementation of the response assessment in Neuro-Oncology Criteria in the HERBY Trial of pediatric patients with newly diagnosed high-grade gliomas. AJNR Am J Neuroradiol. 2019;40(3):568–575.
36. Rodriguez Gutierrez D, Jones C, Varlet P, et al. Radiological evaluation of newly diagnosed non-brainstem pediatric high-grade glioma in the HERBY phase II trial. Clin Cancer Res. 2020;26(8):1856–1865.
37. Varlet P, Le Teuff G, Le Deley MC, et al. WHO grade has no prognostic value in the pediatric high-grade glioma included in the HERBY trial. Neuro Oncol. 2020;22(1):116–127.
38. Martinez-Ricarte F, Mayor R, Martinez-Sáez E, et al. Molecular diagnosis of diffuse gliomas through sequencing of cell-free circulating tumor DNA from cerebrospinal fluid. Clin Cancer Res. 2018;24(12):2812–2819.
39. Piccioni DE, Achrol AS, Kiedrowski LA, et al. Analysis of cell-free circulating tumor DNA from cerebrospinal fluid. Clin Chem. 2016;62(6):842 e825.
40. Thompson JC, Yee SS, Troxel AB, et al. Detection of therapeutically targetable driver and resistance mutations in lung cancer patients by next-generation sequencing of cell-free circulating tumor DNA. Clin Cancer Res. 2016;22(3):572–572.
41. Mouliere F, Chandrananda D, Piskorz AM, et al. Enhanced detection of circulating tumor DNA by fragment size analysis. Sci Transl Med. 2018;10(468):eaat4921.
42. Christensen E, Birkenkamp-Demtröder K, Sethi H, et al. Early detection of metastatic relapse and monitoring of therapeutic efficacy by ultra-deep sequencing of plasma cell-free DNA in patients with urothelial bladder carcinoma. J Clin Oncol. 2019;37(18):1547–1557.
43. Hirotsu Y, Otake S, Ohyama H, et al. Dual-molecular barcode sequencing detects rare variants in tumor and cell free DNA in plasma. Sci Rep. 2020;10(1):3391.